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Purpose: Prostate-specific antigen (PSA) is a useful biomarker of prostate cancer (PCa). 
High-risk localized PCa is defined using T stage, Gleason score (GS), and PSA. However, 
PSA level defining high-risk PCa is at most 20 ng/mL. In PCa patients with high PSA, it 
is unclear whether PSA itself can be a prognostic factor. Methods: Of 642 patients who 
were diagnosed as PCa, 90 patients with PSA > 100 ng/mL were retrospectively analyzed. 
Patients were divided into three groups according to PSA level: very high (> 1000 ng/mL), 
moderately high (200 – 1000 ng/mL), and slightly high (100 – 200 ng/mL). Results: 
There were no significant differences in overall survival or PCa-specific survival 
(PCaSS) among the three groups. Regardless of PSA level, high M stage and GS 
significantly reduced PCaSS. When the risk classification was made using M stage and 
GS (high risk = M1 and GS ≥ 9, low risk = M0 and GS < 9, and intermediate risk = 
others), PCaSS was significantly different among high-, intermediate-, and low-risk 
groups with 5-year survival rates of 58.2%, 80.6%, and 100%, respectively. Although 
there were no differences in treatment performed during the castration-resistant stage, 
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patients undergoing alternative anti-androgen and zoledronic acid treatment had better 
PCaSS after being castration-resistant. Conclusions: As PSA could not be a prognostic 
factor in PCa patients with high PSA > 100 ng/mL, the novel risk classification using M 
stage and GS may help clinicians to predict PCaSS and to plan follow-up schedules after 
diagnosis. 
 
Key words: Prostate-specific antigen, Prostate cancer, TNM classification, Gleason score, 





Prostate-specific antigen (PSA) is useful as a biomarker of disease progression and 
prognosis in prostate cancer (PCa) patients in addition to TNM classification and Gleason 
score (GS). High-risk localized PCa is defined using T stage, Gleason score, and PSA; 
however, PSA level used to define high-risk PCa is at most 20 ng/mL (D'Amico et al. 
1998). Nomograms such as the Partin table also focus on PSA < 10 ng/mL for localized 
PCa (Naito et al. 2005; Partin et al. 2001). Meanwhile, little attention has been paid to 
patients with high PSA > 100 ng/mL regardless of localized or metastatic disease. PSA 
screening systems in Western countries, such as the USA and European countries, are 
well established because of the high prevalence and high mortality rate of PCa (Siegel et 
al. 2013; Ferlay et al. 2010; Andriole et al. 2009; Schroder et al. 2009). Therefore, PCa 
patients with high PSA > 100 ng/mL may rarely be found. However, around 25% of PCa 
patients were found with PSA > 100 ng/mL in Japan (Cooperberg et al. 2009), and 
probably more PCa patients would be found with high PSA in other Asian and developed 
countries. For clinicians, PSA is often the earliest information of PCa patients among PCa 
risk factors because GS is found with PCa diagnosis on biopsy specimens and TNM 
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classification is determined with radiological examinations after diagnosis of PCa. In 
such PCa patients with high PSA, clinicians tend to predict poorer prognosis associated 
with higher PSA; however, it is still unclear whether PSA itself is actually a prognostic 
factor. As shown in Fig. 1, the PCa patient with a PSA level of 4182 ng/mL at diagnosis 
lived much longer than the patient with a PSA level of 108 ng/mL at diagnosis who died 
of PCa, in contrast to our initial expectations. In addition, it is unclear which types of 
treatment after being castration-resistant affect patient prognosis in men with PSA > 100 
ng/mL at diagnosis. In this study, we examined whether PSA can predict patient 
prognosis in PCa patients with high PSA > 100 ng/mL and clarified factors and treatments 
that affect the survival of such PCa patients. 
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Materials and Methods 
Of 642 patients who were diagnosed as having PCa at Kanazawa University Hospital 
between January 2000 and December 2010, 90 patients with PSA > 100 ng/mL were 
retrospectively analyzed with regard to their backgrounds, treatments, and survival. The 
patients were divided into three groups based on their PSA levels, i.e., very high (VH, > 
1000 ng/mL), moderately high (MH, 200 – 1000 ng/mL), and slightly high (SH, 100 – 
200 ng/mL). 
Overall survival (OS), PCa-specific survival (PCaSS), and castration-resistant PCa 
(CRPC)-free survival (CFS) were compared among these groups. Three patients for 
whom the date of being CRPC was unclear were removed from the analysis of CFS. In 
addition, other risk factors were also examined to determine whether their prognostic 
significance. In addition, to clarify the better treatment strategy for patients with high 
PSA, PCaSS after being CRPC was analyzed according to the treatment strategy. CRPC 
was defined as the status after three continuous elevations of PSA during 
androgen-deprivation therapy (ADT), including medical or surgical castration with or 
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without anti-androgen treatment. 
Statistical analyses were performed using the commercially available software Prism 
(GraphPad, San Diego, CA). Comparisons between three groups were performed by 
one-way ANOVA. Comparisons of tendencies among different groups were performed 
by chi-square test for trends. Comparisons of survival described as Kaplan–Meier curves 
were performed by Log-rank test or Log-rank test for trends. In all analyses, P < 0.05 was 




OS and PCaSS in overall patients 
All patients underwent combined androgen blockade consisting of luteinizing 
hormone-releasing hormone analog and anti-androgen as primary treatment except one 
patient who was treated with surgical castration alone. OS and PCaSS in all patients are 
shown in Fig. 2, and relatively long survival was estimated; 5-year survival rates of OS 
and PCaSS were 72.2% and 79.1%, respectively, and 10-year survival rates were 51.5% 
and 67.7%, respectively. 
Patient background, OS, PCaSS, and CFS in each group according to PSA value 
Patient backgrounds are shown in Table 1. The highest PSA value at diagnosis was 
16702 ng/mL. Although there were no differences in age or follow-up time among groups, 
T, N, and M stages and GS tended to be worse as PSA increased. However, there were no 
significant differences in OS, PCaSS, and CFS among VH, MH, and SH groups (Fig. 3). 
OS and PCaSS according to T, N, and M stages and GS 
As it was demonstrated that PSA could not be used to predict patient survival when PSA 
value was higher than 100 ng/mL, other factors were examined to determine whether they 
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could be used as prognostic factors in this patient cohort. As shown in Fig. 4, there were 
no differences in OS or PCaSS among each T stage or N stage. On the other hand, there 
were significant differences in both OS and PCaSS among M0, M1b, and M1c stages (P 
= 0.0075 and P = 0.0048, respectively). GS could not predict OS, but there were 
significant differences in PCaSS among each GS group (i.e., GS ≤ 7, GS = 8, and GS ≥ 9, 
P = 0.0166). 
Novel risk classification of PCa with PSA > 100 ng/mL 
Based on the observations that high M stage and GS worsened PCaSS, a novel risk 
classification combining M stage and GS was developed to better predict PCaSS. High 
risk was defined as M1 and GS ≥ 9, low risk was defined as M0 and GS < 9, and 
intermediate risk was defined as neither high nor low risk. With the exception of one 
patient for whom the GS was not available, 89 patients were divided into these risk 
groups; the numbers of patients in the high, intermediate, and low risk groups were 32, 36, 
and 21, respectively. As shown in Fig. 5, PCaSS was clearly distinguished according to 
risk, and this risk classification was a better predictor of PCaSS than using M stage or GS 
alone (P = 0.0039). Five-year survival rates in the high, intermediate, and low risk groups 
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were 58.2%, 80.6%, and 100%, respectively, and 10-year survival rates in these groups 
were 29.1%, 80.6%, and 92.3%, respectively. 
Treatments performed and PCaSS after being CRPC 
As there was no significant difference in CFS among VH, MH, and SH, treatments 
performed during CRPC stage were examined to determine whether they affect PCaSS 
after being CRPC. There were no significant differences in treatments performed among 
VH, MH, and SH groups (Table 2). As shown in Fig. 6, although docetaxel (DTX), 
estramustine phosphate (EMP), and ethinylestradiol (EE) did not improve PCaSS, 
patients who underwent alternative anti-androgen (AA) and zoledronic acid (ZOL) 
therapy had significantly better PCaSS after being CRPC than those who did not (P = 
0.0088 and P = 0.0137). ZOL is usually administered not when PCa has become 
castration-resistant but when bone metastasis is found. Therefore, PCaSS from diagnosis 




As the number of PCa patient with PSA > 100 ng/mL at diagnosis may not be high in 
many Western countries (Cooperberg et al. 2009), there have been very few studies of the 
prognosis in patients with such high PSA. However, the number of patients with PSA > 
100 mg/mL in other countries should not be neglected. In South Korea, PSA at diagnosis 
was more than 100 ng/mL in 18.3% of PCa patients, and this is similar to the rate of 25% 
for Japanese patients with primary ADT (Cooperberg et al. 2009; Jang et al. 2012). Many 
patients with PSA > 100 ng/mL were found clinically; however, there have been no 
assessments of the relation between PSA and prognosis in such cases. For example, as 
shown in Fig. 1, it is unclear whether there are any differences in background or 
prognosis between patients with PSA = 100 ng/mL and PSA = 4000 ng/mL. Compared to 
previous reports of progression-free survival in patients classified according to clinical 
stage, CFS in the overall patient cohort in this study was similar to stage III patients and 
much better than stage IV patients, and OS in the overall patient cohort was between stage 
III and stage IV patients (Hinotsu et al. 2007). These results indicate that even if PSA at 
diagnosis is higher than 100 ng/mL, patients still have better survival than stage IV 
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patients.  Interestingly, when patients were divided into three groups according to PSA 
level, there were no differences in OS, PCaSS, or CFS among groups, indicating that PSA 
is no longer a prognostic factor at levels beyond 100 ng/mL. Although PSA level is 
important for prognosis in patients with PSA < 100 ng/mL, especially between 4 and 20 
ng/mL, prognosis may reach a plateau in those with PSA >100 ng/mL. This result is 
consistent with those of a previous study that showed that the hazard ratio of progression 
in patients with 100 – 500 ng/mL and > 500 ng/mL was similar, compared to patients 
with PSA < 20 ng/mL as a reference (Kitagawa et al. 2013). In contrast, both M stage and 
GS were found to be prognostic factors in PCaSS in this study. In the VH group, each T, 
N, and M stage and GS were significantly higher than those in the SH group. However, 
prognosis was not significantly different among VH, MH, and SH. This discrepancy may 
have been due to the variance in patient background. That is, patients with high M stage 
did not necessarily have high GS in the VH group. The novel risk classification based on 
the data in this study for patients with PSA > 100 ng/mL clearly distinguished PCaSS 
among risk groups and solved the problem that PSA is not useful as a prognostic marker. 
This risk classification was superior to each T, N, and M stage as well as GS for 
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predicting PCaSS. Previously, the risk classification for patients undergoing primary 
ADT was developed as Japan Cancer of the Prostate Risk Assessment (J-CAPRA) by 
Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) and the Japan 
Study Group of Prostate Cancer (J-CaP) using TNM classification, GS, and PSA at 
diagnosis. Patients were scored from 0 to12 by J-CAPRA score and progression-free 
survival rates in each scored patient group were significantly different (Cooperberg et al. 
2009). J-CAPRA score is very useful for predicting the outcome and is applicable to 
patients with both localized and advanced disease. However, scoring may be complicated, 
especially in T stage and GS. The risk classification in this study may be applicable as 
simplified for the specific PCa population with PSA > 100 ng/mL with a simple scoring 
system. 
As the high PSA level may affect treatment outcome, the effects of treatment during 
CRPC on PCaSS were also investigated in this study. DTX was first shown to improve 
OS of CRPC patients with phase III study, and EMP, EE, AA, and ZOL were reported to 
contribute to better prognosis (Tannock et al. 2004; Petrylak et al. 2004: Kojima et al. 
2004; Ueno et al. 2013; Matsumoto et al. 2013; Izumi et al. 2010). DTX, EMP, and EE did 
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not improve PCaSS after CRPC. In Japan, DTX was approved for PCa in 2008 and the 
patient number was relatively low, which may have influenced the outcome. Meanwhile, 
AA improved PCaSS after CRPC. PSA is downstream of androgen/AR signaling, and a 
high level of PSA may indicate highly activated androgen/AR signaling. AA using 
flutamide was reported to decrease the PSA level in 88% of CRPC patients via the 
reduction of adrenal androgens (Narimoto et al. 2010). It is possible that this mechanism 
functioned well in such high PSA patients. However, this may be biased because only 
seven patients did not undergo AA due possibly to their poor condition and were moved 
to DTX treatment immediately. ZOL is administered for patient with bone metastases 
(M1b) for the reduction of skeletal-related events (Saad et al. 2004). Therefore, the 
patients given ZOL may be regarded as having more advanced disease. Nevertheless, 
ZOL improved PCaSS after CRPC. A previous study showed that ZOL improved 
progression-free survival in patients with GS ≥ 8 and suggested that it may have an effect 
in some advanced patients (Ueno et al. 2013). However, ZOL did not improve PCaSS 




This study had a number of limitations. The small sample size may have prevented 
determination of the precise statistical significance of differences between groups. Larger 
prospective studies with longer follow-up periods and data from other ethnic 
backgrounds are needed to confirm our findings. Moreover, as a variety of anti-neoplastic 
treatments, including DTX, AA, EMP, EE, and others not described here for CRPC, were 
performed, some outcomes may not have been impacted only by M stage and GS or by 
AA and ZOL. 
This is the first report showing the reduced meaning of PSA at diagnosis when the value is 
more than 100 ng/mL and the concise and useful risk classification of patients with PSA > 
100 ng/mL. In addition, AA and ZOL may bring about better outcomes in CRPC patients 
with PSA > 100 ng/mL. These findings may help clinicians to predict PCaSS and to plan 
appropriate follow-up schedules after diagnosis. 
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Fig 1. Cases with PSA > 100 ng/mL 
PSA at diagnosis in Case 1 and Case 2 was more than 4000 and around 100 ng/mL, 
respectively. Generally, prognosis of Case 1 with higher T and N stage than Case 2 
seemed to be worse than that of Case 2. However, survival time of Case 1 was much 
longer than that of Case 2. CAB = combined androgen blockade, ZOL = zoledronic acid, 
AA = anti-androgen, EMP = estramustine phosphate. 
Fig 2. OS and PCaSS in overall patients 
Five-year survival rates of OS and PCaSS were 72.2% and 79.1%, respectively, and 
10-year survival rates were 51.5% and 67.7%, respectively. 
Fig 3. OS, PCaSS, and CFS in VH, MH, and SH 
Based on PSA at diagnosis, patients were divided into very high (VH, > 1000 ng/mL, n = 
21), moderately high (MH, 200 – 1000 ng/mL, n = 37), and slightly high (SH, 100 – 200 
ng/mL, n = 32) groups. However, there were no significant differences in OS, PCaSS, or 




Fig 4. OS and PCaSS according to T, N, and M stage and GS 
T, N, and M stage and GS were examined to determine whether they can be used as 
prognostic factors in patients with PSA > 100 ng/mL. There were no differences in OS or 
PCaSS among each T and N stage (P = 0.0535 and P = 0.2884 with T stage, respectively, 
and P = 0.2381 and P = 0.1530 with N stage, respectively). On the other hand, there were 
significant differences in both OS and PCaSS among each M stage (P = 0.0075 and P = 
0.0048, respectively). GS could not predict OS (P = 0.1273). However, there were 
significant differences in PCaSS among each GS group (P = 0.0166). 
Fig 5. Novel risk classification of PCa with PSA > 100 ng/mL 
High risk was defined as M1 and GS ≥ 9, low risk was defined as M0 and GS < 9, and 
intermediate risk was defined as neither high nor low risk. The numbers of patients in the 
high, intermediate, and low risk groups were 32, 36, and 21, respectively. PCaSS was 
clearly distinguished according to risk, and this risk classification showed better 
prediction of PCaSS than using M stage or GS alone (P = 0.0039). Five-year survival 
rates in high, intermediate, and low risk groups were 58.2%, 80.6%, and 100%, 
respectively, and 10-year survival rates were 29.1%, 80.6%, and 92.3%, respectively. 
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Fig 6. Treatments performed and PCaSS after being CRPC 
Although docetaxel (DTX), estramustine phosphate (EMP), and ethinylestradiol (EE) did 
not improve PCaSS (P = 0.9936, P = 0.3699, and P = 0.4685, respectively), patients who 
underwent alternative anti-androgen (AA) and zoledronic acid (ZOL) therapy had 
significantly better PCaSS after being CRPC than those who did not (P = 0.0088 and P = 




Table 1. Patient backgrounds 
    VH MH SH P 
n 
 
21 37 32 
 
Median age, yr 73 (60 – 86)   75 (52 – 92) 74.5 (50 – 95) 0.9909 
Median PSA, ng/mL 3349 (1018 – 16702) 281 (203 – 979) 138 (102 – 197) < 0.0001 
T 1, 2 2 8 5 0.0315 
 
3 5 15 19 
 
 
4 14 14 8 
 
N 0 4 20 16 0.0264 
 
1 17 17 16 
 
M 0 1 11 24 < 0.0001 
 
1b 15 21 7 
 
 
1c 5 5 1 
 
GS 6, 7 2 9 15 0.0184 
 
8 5 12 3 
 
 
9, 10 14 16 14 
 
 
NA 1 0 0 
 
Median FU, days 988 (10 – 4165) 1424 (29 – 4218) 1390 (7 – 4612) 0.3409 
CRPC Dev yes 11 22 13 0.2932 
  no 10 15 19   
VH = very high, MH = moderately high, SH = slightly high, GS = Gleason score, NA = not available, 






Table 2. Treatment performed in CRPC patients 
    VH MH SH P 
DTX yes 3 7 2 0.5613 
 
no 8 15 11 
 
ZOL yes 7 15 4 0.0841 
 
no 4 7 9 
 
EMP yes 7 16 7 0.522 
 
no 4 6 6 
 
EE yes 3 9 2 0.2749 
 
no 8 13 11 
 
AA yes 10 19 11 0.8953 
  no 1 3 2   
DTX = docetaxel, ZOL = zoledronate, EMP = estramustine 
phosphate, EE = ethinylestradiol, AA = alternative anti-androgen. 
Other abbreviations are the same as in Table 1.   
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